Belvedere Trading’s Terns Pharmaceuticals TERN Stock Holding History

Belvedere Trading’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,500	Closed	-$13.1K	–	951
2023 Q2	$13.1K	Buy	+1,500	New	+$17.5K	﹤0.01%	699

Other funds holding TERN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Belvedere Trading's TERN Position: Q1 2024 in Review

Belvedere Trading sold out of Terns Pharmaceuticals (TERN) in Q1 2024, closing a stake of 25,963 shares — an estimated $169K sold.

Belvedere Trading first reported a position in TERN in Q2 2023 and held it in 3 quarters. The position peaked at $309K in Q2 2023. 112 funds tracked by Wall St. Rank hold TERN as of Q1 2024.

Belvedere Trading reported no remaining Terns Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Belvedere Trading sold 25,963 Terns Pharmaceuticals shares in Q1 2024, an estimated $169K.
Belvedere Trading first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 3 quarters.
Belvedere Trading's Terns Pharmaceuticals position peaked at $309K in Q2 2023.
112 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.